If you have reached this post, maybe you have been recently diagnosed with inflammatory bowel disease or know someone who has been. They are very common: over two million people in Europe live with an IBD, being Crohn’s disease and Ulcerative colitis the most widely spread. The principal characteristic of IBD conditions is the swelling of the digestive tract, which … Read More
April New Deal Reads
1. Targeting JAK-STAT signal transduction in IBD. Soendergaard C. et al. Pharmacology & Therapeutics 192(2018): 100-111 Antibody-based biological drugs were a significant advance for IBD treatments, but unfortunately a high percent of patients doesn’t respond well to this therapy highlighting the need for alternative therapies. Recent studies have shown the great potential of JAK inhibitors to face this unmet medical … Read More
Keep Calm and research on! Consortium meeting in London
Six months passed by since our last meeting in Barcelona so it was time for another face to face meeting for the members of the New Deal consortium. This time in London and hosted by our partners from BOYDS we celebrated our third Annual Meeting to discuss about our progress and define the future steps of our project. Moreover we … Read More
